|
Former Merck Executive Dr. Barry Garfinkle Joins PBS Biotech, Inc. Scientific Advisory Board
Biotech expert provides technical, regulatory and leadership to the fast growing bioreactor company. Will assist firm’s market intro and shape quality standards.
Camarillo, California, May 25, 2011 – PBS Biotech, Inc., a developer of state of the art single-use bioreactors used in the fast growing biotechnology market, announced today Dr. Barry Garfinkle, former vice president of Biological Sciences and Strategy of Merck & Co., a global research-driven pharmaceutical company, has joined the firm’s Scientific Advisory Board which includes accomplished executives, business leaders, and scientists from the leading biopharmaceutical companies and academic institutes. PBS Biotech’s bioreactors help cut costs and accelerate time to market for worldwide makers of drugs, vaccines and biosimilars.Dr. Garfinkle brings over 30 years experience in developing and manufacturing of vaccines, biological and sterile pharmaceuticals to PBS Biotech management team helping shape the company’s product design, market positioning and growth as the next generation single-use bioreactor. “Barry has a broad range of expertise and success in facility design, validation and start up, regulatory affairs and business leadership that will provide significant value to our company as we introduce our single-use bioreactors to the market,” said Dr. Brian Lee, president and co-founder of PBS Biotech. “His knowledge of materials, regulatory issues and process of R&D to manufacturing as well as market dynamics are invaluable in helping us provide unequalled benefits to customers,” he said. Before leading the Biological and Strategy team at Merck, Dr. Garfinkle was for nearly a decade Merck’s VP of Technology and Engineering overseeing all facility design, technical transfer from research, plant start up and technical support for all sterile and vaccine products at Merck. As VP of Merck’s Vaccine Policy he led global quality activities and served as head of Merck’s interaction with the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation & Research (CBER). Dr. Garfinkle has a strong background in regulatory and quality with FDA, CBER, EU and Australia troubleshooting of biological processes and productivity improvements. “Dr. Lee and the PBS Biotech team have developed a product line of bioreactors with the potential to transform the industry’s adoption of single-use technology,” said Dr. Garfinkle. “These systems offer all the features and benefits customers are seeking to make their R&D to manufacturing operations more competitive, while driving out costs and improving overall efficiency,” he said, adding the units are well suited to help advance the development of biosimilars as well as new drugs and vaccines worldwide. Dr. Garfinkle currently heads his own biopharma consulting firm Barry Garfinkle & Associates LLC, Philadelphia, PA. He earned a PhD in microbiology and virology from Penn State University and was a postdoctoral fellow at Roche Institute of Molecular Biology, Nutley, NJ. About PBS Biotech PBS Biotech, Inc. is a US corporation that designs and manufactures fully scalable and easy to use single-use bioreactors used by global biotechnology organizations. The company has patented innovative industrial designs and advanced software driven control systems that produce low shear cell culture solutions improving operational flexibility and process efficiency, reducing operating costs and accelerating time to market for biotechnology customers. With headquarters in Camarillo, CA., PBS Biotech is a member of the BioProcess Systems Alliance (BPSA). Contact: Rick Sullivan, VP Sales & Marketing +1 435-757-3198 |
|
|